Overview
Spherix’s coverage of the bone and mineral metabolism focuses on the complex treatment of secondary hyperparathyroidism (SHPT), vitamin D deficiency, and hyperphosphatemia, tracking treatment trends and the uptake of products as they release into established markets. Covering includes perspective from both nephrologists as well as renal dietitians, and encompasses treatment paradigms for both non-dialysis and dialysis patients.
Services Available
Trending market evolution
Bone and Mineral Metabolism (US) - quarterly, n=200
Renal Dietitians (US) - semiannual, n=100
Exploring the patient journey
Bone and Mineral Metabolism Disorders in CKD Non-Dialysis (US) - n=1,000 patient charts
Bone and Mineral Metabolism Disorders in Dialysis (US) - n=1,000 patient charts
Bone and Mineral Metabolism Disorders in Incident Dialysis (US) - n=1,000 patient charts
Benchmarking new brand performance
Tenapanor (Ardelyx) in Hyperphosphatemia (US)*
*Pending approvals and launch
Gauging impact of disruptive events
Feedback from ASN Virtual Kidney Week Conference 2021 (US)
Multi-Specialty Impact of COVID-19 (US)
Renal Pipeline Tracker